Clinical Trials
138 trialsDefining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Columbia University
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
ALLELE
Pierre Fabre Medicament
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
National Institutes of Health Clinical Center (CC)
SPiReL
Sunnybrook Health Sciences Centre
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
inMMyCAR
Kelonia Therapeutics, Inc.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
OPAL
AVM Biotechnology Inc
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
Georgetown University
ESCALADE
Acerta Pharma BV
CLOVER-WaM
Cellectar Biosciences, Inc.
ACCESS
Center for International Blood and Marrow Transplant Research
FOCUS
Azienda Ospedaliero-Universitaria di Parma
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Azienda Ospedaliero-Universitaria di Parma
GRALE
Baylor College of Medicine
DETERMINE
Cancer Research UK
Virtual Rehabilitation for Cancer Survivors
University Health Network, Toronto
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
University of Michigan Rogel Cancer Center
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Mayo Clinic
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
UNC Lineberger Comprehensive Cancer Center
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
CASPALLO
Baylor College of Medicine
DOTTI
Baylor College of Medicine
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies
Viracta Therapeutics, Inc.
PHANTASTIC
University of Liverpool
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
Oncternal Therapeutics, Inc
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)
Celgene